Baret News – Lifestyle
Author:
Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
April 14, 2026
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
April 13, 2026
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
April 13, 2026